A prospective cross-sectional study of serum IL-17A in antisynthetase syndrome.

Clinical Rheumatology
Gustavo Luiz Behrens PintoSamuel K Shinjo

Abstract

The pro-inflammatory interleukin (IL)-17A serum has been characterized in several systemic autoimmune diseases, but not in antisynthetase syndrome (ASS). Therefore, the present study aims firstly to assess the serum level of the IL-17A in patients with ASS, comparing with healthy individuals, and secondly to analyze prospectively this IL in patients with refractory ASS undergoing rituximab treatment. A cross-sectional, single-center study that included 64 patients with ASS who were age-, gender-, and ethnicity-matched to 64 healthy individuals. Disease status was measured by the International Myositis Assessment and Clinical Studies Group (IMACS) set scores. Secondarily, the patients with refractory disease treated with rituximab were prospectively followed for 12 months. The IL-17A was assessed by the ELISA method. The mean age of the patients was 44.8 ± 11.8 years, with a predominance of female gender and Caucasian. The median serum IL-17A level was higher in ASS patients compared with healthy individuals: 9.7 (9.1-10.4) vs. 7.7 (5.7-9.0) pg/mL, respectively, and P < 0.001. However, the demographical, clinical, and laboratory data indicates that disease status did not correlate with serum levels of the IL-17A in ASS patients....Continue Reading

References

Nov 16, 2001·Rheumatology·F W MillerUNKNOWN International Myositis Outcome Assessment Collaborative Study Group
Jul 2, 2003·Health and Quality of Life Outcomes·Bonnie Bruce, James F Fries
Jan 29, 2010·Journal of Clinical Immunology·Xiao Qi ChenMiao Yang
Jul 28, 2010·Proceedings of the National Academy of Sciences of the United States of America·Meike MitsdoerfferVijay K Kuchroo
Jan 15, 2011·Scandinavian Journal of Rheumatology·H ShenW Xiao
Feb 26, 2011·Immunity·Yoichiro IwakuraSusumu Nakae
Mar 15, 2011·Arthritis and Rheumatism·Frank L van de VeerdonkLeo A B Joosten
Feb 22, 2012·Current Rheumatology Reports·Anne Tournadre, Pierre Miossec
Jun 26, 2013·Current Rheumatology Reports·Baptiste Hervier, Olivier Benveniste
Nov 13, 2013·Revista brasileira de reumatologia·Fernando Henrique Carlos de SouzaSamuel Katsuyuki Shinjo
Jan 16, 2014·Autoimmunity Reviews·Michael MahlerMarvin J Fritzler
Jul 24, 2014·Neuromuscular Disorders : NMD·Ellen M Moran, Frank L Mastaglia
Nov 8, 2014·Scandinavian Journal of Rheumatology·A NotarnicolaF Iannone
Jun 13, 2015·Archivum Immunologiae Et Therapiae Experimentalis·Jacek TabarkiewiczKrzysztof Giannopoulos
Sep 19, 2015·BMC Musculoskeletal Disorders·Ann M ReedUNKNOWN RIM Study Group
May 4, 2017·The Journal of Rheumatology·Jingli ShiGuochun Wang
Sep 22, 2018·Current Opinion in Rheumatology·Laure GallayBaptiste Hervier
Jan 19, 2019·Advances in Rheumatology·Fernando Henrique Carlos de SouzaSamuel Katsuyuki Shinjo
Jan 24, 2019·Advances in Rheumatology·Fernando Henrique Carlos de SouzaSamuel Katsuyuki Shinjo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

The New Zealand Medical Journal
Ya-Chu May Tsai, Louise E Nardone
Der Urologe. Ausg. A
Herbert Rübben
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde
J V Larsen
© 2021 Meta ULC. All rights reserved